Wastesson JW, Canudas-Romo V, Lindahl-Jacobsen R, Johnell K. Remaining life expectancy with and without polypharmacy: a register-based study of Swedes aged 65 years and older. J Am Med Dir Assoc. 2016;17(1):31–5.

Article  PubMed  PubMed Central  Google Scholar 

Salvi F, Marchetti A, D’Angelo F, Boemi M, Lattanzio F, Cherubini A. Adverse drug events as a cause of hospitalization in older adults. Drug Saf. 2012;35(Suppl 1):29–45.

Article  PubMed  Google Scholar 

Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US emergency department visits for outpatient adverse drug events, 2013–2014. JAMA. 2016;316(20):2115–25.

Article  PubMed  PubMed Central  Google Scholar 

Wastesson JW, Fastbom J, Johnell K. Expanding the proportion of life with polypharmacy in Sweden: 2006–2013. J Am Med Dir Assoc. 2016;17(10):957–8.

Article  PubMed  Google Scholar 

Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002–12.

Article  CAS  PubMed  Google Scholar 

Calderon-Larranaga A, Vetrano DL, Onder G, Gimeno-Feliu LA, Coscollar-Santaliestra C, Carfi A, et al. Assessing and measuring chronic multimorbidity in the older population: a proposal for its operationalization. J Gerontol A Biol Sci Med Sci. 2017;72(10):1417–23.

PubMed  Google Scholar 

Johnell K, Fastbom J. Comparison of prescription drug use between community-dwelling and institutionalized elderly in Sweden. Drugs Aging. 2012;29(9):751–8.

Article  PubMed  Google Scholar 

Wastesson JW, Cedazo Minguez A, Fastbom J, Maioli S, Johnell K. The composition of polypharmacy: a register-based study of Swedes aged 75 years and older. PLoS ONE. 2018;13(3): e0194892.

Article  PubMed  PubMed Central  Google Scholar 

Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016;353: i2868.

Article  PubMed  PubMed Central  Google Scholar 

Trevisan C, Limongi F, Siviero P, Noale M, Cignarella A, Manzato E, et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug-drug interactions. Aging Clin Exp Res. 2019;33:49–56.

Article  PubMed  Google Scholar 

Ernst R, Fischer K, de GoRezende Costa Molino C, Orav EJ, Theiler R, Meyer U, et al. Polypharmacy and kidney function in community-dwelling adults age 60 years and older: a prospective observational study. J Am Med Dir Assoc. 2020;21(2):254–91.

Article  PubMed  Google Scholar 

Morin L, Calderon Larranaga A, Welmer AK, Rizzuto D, Wastesson JW, Johnell K. Polypharmacy and injurious falls in older adults: a nationwide nested case-control study. Clin Epidemiol. 2019;11:483–93.

Article  PubMed  PubMed Central  Google Scholar 

Katsimpris A, Linseisen J, Meisinger C, Volaklis K. The association between polypharmacy and physical function in older adults: a systematic review. J Gen Intern Med. 2019;34(9):1865–73.

Article  PubMed  PubMed Central  Google Scholar 

Rochon PA, Gurwitz JH. The prescribing cascade revisited. Lancet. 2017;389(10081):1778–80.

Article  PubMed  Google Scholar 

Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf. 2018;17(12):1185–96.

Article  PubMed  Google Scholar 

Wastesson JW, Fritzell J, Burstrom B, Johnell K, Fastbom J. Regional variations in excessive polypharmacy and potentially inappropriate drug use among older adults in Sweden: trends from 2006 to 2020. Front Pharmacol. 2023;14:1030849.

Article  PubMed  PubMed Central  Google Scholar 

Reeve E, Wiese MD, Mangoni AA. Alterations in drug disposition in older adults. Expert Opin Drug Metab Toxicol. 2015;11(4):491–508.

Article  PubMed  Google Scholar 

Cerreta F, Eichler HG, Rasi G. Drug policy for an aging population—the European Medicines Agency’s geriatric medicines strategy. N Engl J Med. 2012;367(21):1972–4.

Article  CAS  PubMed  Google Scholar 

Tinetti ME. The gap between clinical trials and the real world: extrapolating treatment effects from younger to older adults. JAMA Intern Med. 2014;174(3):397–8.

Article  PubMed  Google Scholar 

Watts G. Why the exclusion of older people from clinical research must stop. BMJ. 2012;344: e3445.

Article  PubMed  Google Scholar 

Hilmer SN, Schwartz J, Petrovic M, Walker LE, Thurmann P, Le Couteur DG (2024) Addressing the gaps in evaluation of new drugs for older adults: strategies from the International Union of Basic and Clinical Pharmacology (IUPHAR) Geriatric Committee. J Am Geriatr Soc

Liau SJ, Lalic S, Sluggett JK, Cesari M, Onder G, Vetrano DL, et al. Medication management in frail older people: consensus principles for clinical practice, research, and education. J Am Med Direc Assoc. 2021;22(1):43–9.

Article  Google Scholar 

Tan ECK, Sluggett JK, Johnell K, Onder G, Elseviers M, Morin L, et al. Research priorities for optimizing geriatric pharmacotherapy: an international consensus. J Am Med Dir Assoc. 2018;19(3):193–9.

Article  PubMed  Google Scholar 

Zhang HT, McGrath LJ, Ellis AR, Wyss R, Lund JL, Sturmer T. Restriction of pharmacoepidemiologic cohorts to initiators of medications in unrelated preventive drug classes to reduce confounding by frailty in older adults. Am J Epidemiol. 2019;188(7):1371–82.

Article  PubMed  PubMed Central  Google Scholar 

Johnell K. The controversies surrounding polypharmacy in old age—where are we? Expert Rev Clin Pharmacol. 2018;11(9):825–7.

Article  CAS  PubMed  Google Scholar 

Johnell K. Inappropriate drug use in people with cognitive impairment and dementia: a systematic review. Curr Clin Pharmacol. 2015;10(3):178–84.

Article  PubMed  PubMed Central  Google Scholar 

Bonfiglio V, Umegaki H, Kuzuya M. Potentially inappropriate medications and polypharmacy: a study of older people with mild cognitive impairment and mild dementia. J Alzheimers Dis. 2019;71(3):889–97.

Article  CAS  PubMed  Google Scholar 

Brenowitz WD, Yaffe K. Observational studies in Alzheimer disease: bridging preclinical studies and clinical trials. Nat Rev Neurol. 2022;18(12):747–57.

Article  PubMed  PubMed Central  Google Scholar 

Banzi R, Camaioni P, Tettamanti M, Bertele V, Lucca U. Older patients are still under-represented in clinical trials of Alzheimer’s disease. Alzheimers Res Ther. 2016;8:32.

Article  PubMed  PubMed Central  Google Scholar 

Leinonen A, Koponen M, Hartikainen S. Systematic review: representativeness of participants in RCTs of acetylcholinesterase inhibitors. PLoS ONE. 2015;10(5): e0124500.

Article  PubMed  PubMed Central  Google Scholar 

Fujita K, Masnoon N, Mach J, O’Donnell LK, Hilmer SN. Polypharmacy and precision medicine. Camb Prism Precis Med. 2023;1: e22.

Article  PubMed  PubMed Central  Google Scholar 

Jennings E, Gallagher P, O’Mahony D. Detection and prevention of adverse drug reactions in multi-morbid older patients. Age Ageing. 2019;48(1):10–3.

Article  PubMed  Google Scholar 

Xu J, Zhang H, Zhang H, Bian J, Wang F. Machine learning enabled subgroup analysis with real-world data to inform clinical trial eligibility criteria design. Sci Rep. 2023;13(1):613.

Article  CAS  PubMed  PubMed Central  Google Scholar 

OECD (2018) Test No. 452: Chronic Toxicity Studies 2018.